Management of Ashrigdhar by a traditional yog (chopchini, muchukunda, marich and sunthi )

A Pharmaco-clinical evaluation of Madhusnuhi(Smilax Ovalifolia Roxb.) with special reference of ashrigdara

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024436

Enrollment

Registered

2020-04-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N938- Other specified abnormal uterine and vaginal bleeding

Interventions

Intervention1: Madhusnuhi(smilax ovalifolia) 5gm,sunthi(zinziber official)2.5gm,Marich(piper nigram)1.5gm,Muchukunda(pterospermum acerifolium)5gm: Dose- 5 gm once in a day Route- Oral administration.

Eligibility

Inclusion criteria

Inclusion criteria: 1.patients having signs and symptoms of Asridgara(DUB)such as excessive bleeding per vaginum, backaches, pain in lower abdomen and weakness

Exclusion criteria

Exclusion criteria: 1.age below 18 years 2.chronic cases of >1 years history 3.Bleeding due to erosion, cancer and fibroid 4.Bleeding from the site other than the uterus 5.suffering with systemic disease like Diabetes, Hypertension, Malignsncy, tuberculosis, renal diseases,liver diseases etc.

Design outcomes

Primary

Measure	Time frame
Relief in signs and symptoms of Asridgara (DUB) such as excessive bleeding per vaginum, Backaches, pain in lower abdomen and weakness etc. and as described in Ayurvedic classics.Timepoint: 7 days	—

Secondary

Measure	Time frame
Haemoglobin befor and after the clinical trial.Timepoint: 2 Month.	—

Countries

India

Contacts

Public ContactProf RN Acharya

Institute of post graduate teaching and research in Ayurved, jamnagar GUJARAT

drrnacharya@gmail.com9924585855

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026